18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
03/04/2019: Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.
Global industry news
AbbVie's new launches Skyrizi, Rinvoq aren't getting enough credit: analyst
BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS
Sanofi strategy exec Mansuri jumps ship ahead of new CEO's big reveal
+7 495 442 37 85
+7 985 908 58 18
Registration of Medical Drugs in Russia
Registration of Pharmaceuticals in Russia
Registration of Pharmaceutical Dossier Variations in Russia
Registration of Pharmaceuticals in CIS
Clinical Studies in Russia
Clinical Studies for Registration of Pharmaceuticals in Russia
International Phase III Clinical Studies
Phase I, Phase II (IIa, IIb) Clinical Studies
Preclinical Studies in Russia
Preclinical Studies for Registration of Pharmaceuticals in Russia
Preclinical Studies for Registration of Biopharmaceuticals in Russia
In Vitro Preclinical Studies in Russia
Regulatory Consulting in Russia and EEU
Certification of Medical Drugs and Medical Devices in Russia
Registration of Medical Devices in Russia
Russian GMP inspection of pharmaceutical manufacturers
Regulatory Events Russia
Russian Regulatory News
You are here:
Pharegis LLC / ООО "Фареджис"
3-1 Begovaya str. ("NordStar Tower", 31st flr), Moscow, Russia 125284
Legal & postal address:
11A-11 Cherkizovskaya B. str., Moscow, Russia 107392
TAX ID (TIN): 7718278100
+7 495 442 37 85 9am-6pm GMT+3
+ 7 495 442 37 85
+ 7 985 908 58 18
Send an Email
Send a copy to yourself
SHARE THIS BY:
Create an account
Forgot your username?
Forgot your password?
Drugs.com - New Drug Approvals
FDA Approves Xcopri (cenobamate) for the Treatment of Partial-Onset Seizures in Adults
FDA Approves Calquence for Adults with Chronic Lymphocytic Leukemia
FDA Approves Givlaari (givosiran) for Acute Hepatic Porphyria
FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira
FDA Approves Adakveo (crizanlizumab-tmca) to Reduce Frequency of Pain Crises in Individuals Living with Sickle Cell Disease
News and press releases
Dutch authorities hand over final building to EMA in Amsterdam, , 15/11/2019
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2019 (updated), CHMP, 15/11/2019
EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots, CHMP, 15/11/2019
Measures to minimise risk of serious side effects of multiple sclerosis medicine Lemtrada, CHMP, 15/11/2019
Drugs.com - Clinical Trials
Results of a Randomized Study of the Safety and Efficacy of Cenobamate in Adults with Uncontrolled Focal Seizures Published in The Lancet Neurology
PARAMUS, N.J., Nov. 13,...
Anifrolumab Demonstrated Superiority Across Multiple Efficacy Endpoints in Patients with Systemic Lupus Erythematosus in Phase III TULIP 2 Trial
November 11, 2019 --...
AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML
Genentech’s Risdiplam Meets Primary Endpoint In Pivotal SUNFISH Trial in People With Type 2 or 3 Spinal Muscular Atrophy
South San Francisco, CA --...
PharmaTimes: PharmaTimes Website RSS
FDA nod for Calquence in CLL
Labour manifesto needs to ‘go further’ with NHS, says BMA
ViiV inks bNAb deal with National Institutes of Health
Cognitant wins £30k for VR pilot
Health sector ups cyber security by more than 500%
Terms of Service
Sample Non-Disclosure Agreement